Graft failure (GF) after allo-SCT is a serious complication with high mortality. 1, 2 Discrimination between rejection and poor graft function (PGF) can be made by chimerism analysis. In rejection, chimerism status is mixed, with the presence of recipient cells, whereas full donor chimerism is present in PGF. In patients with rejection, a second transplant preceded by a conditioning regimen should be considered. [1] [2] [3] PGF may be transient if caused by CMV infection or by drugsfor instance, ganciclovir. 4 In this case, supportive therapy and growth factors can be used until clearance of CMV infection or change of therapy has ensued. If the PGF endures, however, the prognosis is dismal with infections or organ failure being a predictable outcome, which can only be avoided by a second transplant. 5 Importantly, patients with PGF may not need conditioning before a second transplant with the same donor, as they possess the donor's immune system. Use of booster infusions has previously been reported with some promising results, albeit several studies used BM as booster source, chimerism studies were often absent, and CD34 þ selection was not always performed. [4] [5] [6] [7] [8] [9] We performed a retrospective study of patients treated according to our 'booster protocol' at our institution. The criteria in this protocol were as follows: (1) PGF not caused by medication or infection, (2) full donor chimerism in BM or peripheral blood, (3) hypocellular BM with 10% cellularity or less, (4) no active GVHD, (5) no relapse of hematological malignancy and (6) original donor available.
Between January 2002 and June 2011, 562 adult patients received allo-SCT at our center, and among these, 18 patients with PGF fulfilled the criteria for the booster protocol (Table 1 ). All primary grafts were T-cell replete. Primary PGF was defined as failure to obtain a peripheral blood neutrophil count X0.5 Â 10 9 /L and/or a continued requirement for platelet transfusions. Secondary PGF was defined with same criteria as primary PGF but occurring after initial engraftment. Two (11%) patients had primary and 16 (89%) had secondary PGF. BM cellularity was evaluated in all patients using biopsy. The median neutrophil count in blood was 0.54 Â 10 9 /L (range: 0-4.7); all neutropenic patients failed to respond to growth factors. The median platelet count was 14 Â 10 9 /L (range: 4-58). Six (33%) patients had a PCRpositive CMV infection before PGF diagnosis. The CMV infection was treated in all patients before PGF diagnosis, and none received anti-CMV therapy at that time point. Engraftment after booster cell infusion was defined as the first of three consecutive days with neutrophils in peripheral blood X0.5 Â 10 9 /L, and the first day for three consecutive days with platelet count X50 Â 10 9 /L without platelet transfusions, whichever occurred last. Unseparated donor chimerism was 498% in all cases; in CD4 þ and CD8 þ T-lymphocyte subsets, donor chimerism were medians of 99% (82-99%) and 99% (82-99%), respectively. The booster grafts were all prepared from G-CSF-stimulated PBSC grafts. The median fraction of CD34 þ cells in the grafts was 92%.
The Miltenyi CliniMACS (Miltenyi Biotec, Cologne, Germany) system was used for the CD34 þ selection of the grafts. In one patient suffering from disseminated Fusarium infection, the product was split, and a CD3 depletion was performed in addition to a CD34 selection in order to include granulocytes, monocytes and NK cells in the graft. Thirteen (72%) patients achieved engraftment after booster cells (Figure 1 ). Five patients died without engraftment-death causes were infections and organ toxicity. None of the engrafted patients experienced subsequent GF. Four (22%) patients developed acute GVHD, two patients had grades I-II, one patient had grade III and one patient had grade IV. The two patients with grades III and IV GVHD succumbed from their GVHD. In a previous study, unmanipulated booster cells were administered and 55% of the patients developed GVHD. 6 It is conceivable that the low content of T cells in our booster grafts resulted in a lower incidence of GVHD. Chronic GVHD was later diagnosed in nine patients, seven with extensive disease and two with limited. OS at 2 years was 48, and 40% at 9 years with a median observation time of 4.1 years in surviving patients.
Established risk factors for GF are a BM graft, HLA mismatch, low cell number in the graft and unrelated donor or T-cell depletion of the graft. Risk factors in the first transplant in our patients were that 12 (67%) received a BM graft, and we had two patients with HLA mismatch, one with an allele mismatch at HLA-DR and one with an Ag mismatch at HLA-C. In addition, three patients received antithymocyte globuline (ATG) as a part of the conditioning regimen. The median number of CD34 þ cells in the PBSC grafts in our GF patients was in the lower 25% percentile of the numbers in the general transplant population in our center. Notably, 6 of 18 patients had myelofibrosis, which is a rare indication for HCT in our institution. A French multicenter study has previously reported a high incidence of GF at 10% among patients with myelofibrosis, although distinction between rejection and PGF was not made. 10 The decision to employ a booster infusion involves contact with the donor and several logistic procedures. We encountered a longer waiting time to achieve the booster product from unrelated donors than related, 23 vs 12 days. We had the positive experience that our request for additional cells was accepted by the donor centers in all cases of unrelated donor. The transplant center has an obligation to ask for supplemental cells only when the chances of a positive outcome are reasonable. With a long-term survival of 40% in a patient population with a very dismal prognosis, we feel that a request for booster cells in PGF fulfills this ethical demand.
In conclusion, we emphasize that chimerism should be evaluated early in patients with GF. If PGF is diagnosed, and infection or drugs is not accountable for the insufficient marrow function, a booster of CD34 þ selected cells from the original donor can be administered without conditioning, ensuring a strong possibility of achieving long-term survival. 
